Last updated: October 2, 2026
Dapagliflozin/metformin hydrochloride is a fixed-dose combination marketed primarily as Xigduo XR by AstraZeneca. The product combines the SGLT2 inhibitor dapagliflozin with extended-release metformin for adults with type 2 diabetes. Its commercial position is supported by the broader Farxiga franchise, but the combination faces generic pressure, limited standalone revenue disclosure, and competition from branded SGLT2 inhibitors, GLP-1 therapies, and low-cost generic metformin.
The core commercial thesis is mixed. Dapagliflozin has become a major cardiorenal medicine with multibillion-dollar franchise sales, while the dapagliflozin/metformin combination has weaker strategic importance because physicians increasingly use dapagliflozin for heart failure and chronic kidney disease without metformin. The combination's value is concentrated in diabetes patients who require both agents and benefit from reduced pill burden.
What is dapagliflozin and metformin hydrochloride?
Dapagliflozin/metformin hydrochloride is an oral fixed-dose combination containing:
| Component |
Pharmacology |
Commercial role |
| Dapagliflozin |
Sodium-glucose cotransporter 2, or SGLT2, inhibitor |
Lowers glucose and provides cardiorenal benefits |
| Metformin hydrochloride |
Biguanide |
First-line glucose-lowering therapy |
| Formulation |
Extended-release tablet |
Supports once-daily administration |
| Main brand |
Xigduo XR |
AstraZeneca originator product |
| FDA application |
NDA 205649 |
Approved in the United States in 2014 |
Xigduo XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not a treatment for type 1 diabetes and is not interchangeable with every dapagliflozin or metformin product because dosage strengths, release characteristics, and renal restrictions differ.[1]
Dapagliflozin is marketed separately as Farxiga in the United States. Metformin hydrochloride is widely available as a low-cost generic. This creates a key commercial tradeoff: the fixed-dose product improves convenience, but patients and payers can often achieve lower cost by prescribing the two components separately.
How large is the dapagliflozin market?
The dapagliflozin market is substantially larger than the dapagliflozin/metformin combination market because dapagliflozin has expanded beyond diabetes.
Dapagliflozin franchise indications
Farxiga is used in the United States for:
- Type 2 diabetes glycemic control
- Reducing hospitalization for heart failure in adults with heart failure
- Reducing the risk of sustained kidney function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease
- Reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in selected heart-failure populations
The cardiorenal indications have changed the economic profile of dapagliflozin. Physicians can prescribe the active ingredient even when metformin is unsuitable, unnecessary, or contraindicated. That limits the proportion of total dapagliflozin revenue that can accrue to Xigduo XR.
AstraZeneca reports Farxiga as a major product franchise but does not separately disclose global revenue for Xigduo XR in its primary financial reporting. Public revenue figures therefore measure dapagliflozin franchise performance, not the fixed-dose combination alone.[2]
What is the financial trajectory of dapagliflozin and metformin hydrochloride?
The financial trajectory has two distinct layers:
- Dapagliflozin franchise growth: Strong, driven by heart failure and chronic kidney disease.
- Xigduo XR growth: More constrained, because metformin is generic and dapagliflozin can be prescribed as Farxiga alone.
AstraZeneca has reported sustained growth in the Farxiga franchise as cardiorenal use increased. The company’s annual reports identify Farxiga as one of its largest growth products, with sales supported by expanded indications and broader physician adoption.[2]
| Financial driver |
Effect on Xigduo XR |
| Greater use of dapagliflozin in chronic kidney disease |
Positive for the molecule, limited benefit for the combination |
| Greater use in heart failure |
Positive for Farxiga, modest direct benefit for Xigduo XR |
| Generic metformin pricing |
Reduces the value of the combination premium |
| Fixed-dose convenience |
Supports adherence and prescription retention |
| Payer rebates |
Pressures net price |
| Generic dapagliflozin entry |
Creates direct erosion risk |
| GLP-1 and dual incretin competition |
Reduces diabetes-only growth potential |
| Renal restrictions on metformin |
Limits use in some cardiorenal patients |
The most important financial conclusion is that Xigduo XR should not be valued as a separate proxy for the entire dapagliflozin business. The combination captures only a portion of the active ingredient's clinical and economic opportunity.
How does Xigduo XR compare with Farxiga and competing drugs?
Xigduo XR versus Farxiga
| Attribute |
Xigduo XR |
Farxiga |
| Active ingredients |
Dapagliflozin plus metformin XR |
Dapagliflozin alone |
| Primary commercial use |
Type 2 diabetes |
Diabetes, heart failure, chronic kidney disease |
| Flexibility |
Lower, because metformin is embedded |
Higher |
| Pill burden |
Lower for patients needing both drugs |
Requires separate metformin if used |
| Cardiorenal positioning |
Indirect |
Direct and central |
| Generic substitution risk |
Combination-specific and component-level |
Dapagliflozin-specific |
| Pricing leverage |
Limited by generic metformin |
Greater while branded protection remains |
Xigduo XR versus Synjardy and other SGLT2 combinations
The main branded fixed-dose competitors include:
- Synjardy and Synjardy XR, empagliflozin/metformin, marketed by Boehringer Ingelheim and Eli Lilly
- Invokamet and Invokamet XR, canagliflozin/metformin, marketed by Janssen
- Glyxambi, empagliflozin/linagliptin
- Qtern, dapagliflozin/saxagliptin
Xigduo XR benefits from dapagliflozin's strong heart-failure and chronic-kidney-disease evidence. Synjardy benefits from empagliflozin's established cardiovascular outcomes profile. Invokamet has faced a more difficult commercial environment because canagliflozin growth has lagged the leading SGLT2 products.
Fixed-dose combinations compete on formulary placement, copay, adherence, renal eligibility, and physician familiarity. Clinical differentiation is less important when payers can substitute individual generic components.
When does dapagliflozin lose exclusivity?
Dapagliflozin's original U.S. compound patent reached its listed expiration in 2020, based on the principal Orange Book patent associated with the active ingredient.[3] Any patent-term adjustment, pediatric exclusivity, later-listed formulation patent, method-of-use patent, or litigation settlement can affect the practical launch date for a particular generic product.
The key distinction is between:
- Molecule-level exclusivity: Protection for dapagliflozin itself.
- Combination protection: Protection for dapagliflozin plus metformin or the extended-release dosage form.
- Use protection: Protection for a specific treatment method.
- Regulatory exclusivity: FDA exclusivity attached to the approved application or indication.
Dapagliflozin is a small molecule, so biosimilar exclusivity does not apply. Competition arrives through abbreviated new drug applications, or ANDAs, rather than through the biosimilar pathway.
What is the Orange Book status of Xigduo XR?
Xigduo XR is an FDA-approved small-molecule drug product listed under NDA 205649. The FDA Orange Book is the controlling source for active patent listings, expiry dates, pediatric extensions, and therapeutic-equivalence determinations.[3]
The Orange Book analysis should separate three categories:
Active-ingredient patents
These relate to dapagliflozin and have the greatest potential to delay generic entry across multiple dapagliflozin products. The primary U.S. compound patent has expired.
Formulation patents
These may cover extended-release dosage forms, tablet composition, release profiles, or specific combinations of dapagliflozin and metformin. Their commercial value depends on whether a generic can design around the claims or launch a non-infringing dosage form.
Method-of-use patents
These can cover treatment of diabetes, heart failure, kidney disease, or other patient populations. Their effect is narrower than a compound patent because an ANDA applicant may use a section viii carve-out for a patented indication, subject to the scope of the remaining labeling.
A current product-level freedom-to-operate review must examine the live Orange Book listing and the ANDA applicant's Paragraph IV certifications. Patent expiry for the dapagliflozin molecule alone does not establish that every Xigduo XR formulation can launch without additional risk.
What generic entry risks exist for Xigduo XR?
Generic entry risk is high at the active-ingredient level and moderate to high for the fixed-dose combination, depending on the remaining formulation claims.
Generic launch scenarios
| Scenario |
Commercial effect |
| Generic dapagliflozin alone launches first |
Erodes Farxiga pricing but may preserve some convenience value for Xigduo XR |
| Generic dapagliflozin/metformin XR launches |
Directly pressures Xigduo XR volume and price |
| Generic metformin remains the only low-cost component |
Patients may switch to separate tablets |
| Authorized generic or settlement launch |
Erosion may begin before full patent expiry |
| Formulation patent survives |
Delays direct substitution but does not protect the molecule broadly |
A generic competitor can also target dapagliflozin monotherapy while leaving Xigduo XR exposed to a separate ANDA strategy. This matters because payers often prefer individual generic ingredients if the cost difference is substantial.
Which companies are challenging dapagliflozin or Xigduo XR?
Generic pharmaceutical companies with established ANDA capabilities are the likely competitive pool, including large Indian and U.S. manufacturers. However, a company should not be treated as an active Paragraph IV challenger without confirmation in FDA records, Abbreviated New Drug Application litigation, or a filed district-court complaint.
The relevant diligence sources are:
- FDA Orange Book patent certifications
- FDA Paragraph IV notice records
- PACER and district-court complaints
- Hatch-Waxman litigation dockets
- AstraZeneca annual reports
- ANDA approval announcements
A reliable competitive assessment must distinguish between a company that markets a generic dapagliflozin product, a company that filed an ANDA, and a company that made a Paragraph IV certification. Those are different legal and commercial events.
What patent litigation affects dapagliflozin and metformin?
Dapagliflozin has generated patent disputes around compound, formulation, and use claims. The most commercially important litigation question is whether an ANDA applicant can enter before the expiry of the relevant Orange Book-listed patent.
Under the Hatch-Waxman framework, a Paragraph IV notice can trigger patent litigation and a statutory 30-month stay of FDA approval, subject to statutory exceptions and court developments. The stay does not automatically prevent all forms of market entry, and a settlement can establish a licensed launch date earlier than the asserted patent expiry.
For Xigduo XR, litigation risk is likely to be more product-specific than for Farxiga because the combination may involve different formulation or dosage-form claims. Publicly disclosed litigation and settlement terms should be reviewed separately for Farxiga, Xigduo XR, and other dapagliflozin combinations.
Are there licensing deals for dapagliflozin/metformin?
AstraZeneca developed and commercialized dapagliflozin in collaboration with Bristol Myers Squibb in earlier stages of the product's development. AstraZeneca later assumed full global rights to dapagliflozin after the collaboration ended.[4]
The historic collaboration is relevant to ownership and development history, but it does not create a current biosimilar-style licensing structure. Generic companies generally enter through regulatory filings rather than voluntary licenses. Regional commercialization agreements, supply arrangements, and authorized-generic deals must be analyzed by territory because rights can differ across the United States, Europe, Japan, China, and emerging markets.
How strong is the patent estate for Xigduo XR?
The patent estate is strategically weaker than it was before dapagliflozin compound-patent expiry.
| Patent layer |
Relative strength |
Reason |
| Dapagliflozin compound |
Low after expiry |
Broad molecule protection has ended |
| Metformin hydrochloride |
Very low |
Long-established generic ingredient |
| Fixed-dose combination |
Moderate if claims remain enforceable |
May delay direct combination substitution |
| Extended-release formulation |
Moderate |
Depends on claim breadth and design-around options |
| Cardiorenal methods of use |
Variable |
Can protect selected indications but not all uses |
| Regulatory exclusivity |
Limited |
Original FDA approval dates are long past |
The estate can still create litigation cost and timing risk, but it is unlikely to preserve long-term monopoly economics comparable to a new chemical entity with unexpired compound claims.
What is the FDA regulatory status?
The FDA approved Xigduo XR in 2014 for adults with type 2 diabetes as an adjunct to diet and exercise.[1] The product carries class-related warnings and precautions involving lactic acidosis, ketoacidosis, volume depletion, renal function, genital and urinary infections, and temporary interruption around certain procedures or clinical conditions.
Metformin limits the eligible population because renal function must be assessed before and during treatment. Dapagliflozin also has renal-use restrictions that vary by indication and dosing objective. This creates a practical barrier to using Xigduo XR in some patients who could still receive dapagliflozin for heart failure or chronic kidney disease.
What are the main commercial risks?
The principal risks are:
- Component substitution: Prescribers can use generic metformin and dapagliflozin separately.
- SGLT2 price erosion: Generic dapagliflozin can reduce the branded premium.
- Indication mismatch: Cardiorenal patients may not need metformin.
- GLP-1 competition: Semaglutide, tirzepatide, and related products compete for diabetes spending.
- Payer control: Formularies can require separate components or impose step therapy.
- Renal limitations: Metformin eligibility narrows as kidney disease advances.
- Limited product disclosure: AstraZeneca does not report Xigduo XR sales separately from broader product and regional reporting.
Key Takeaways
- Xigduo XR combines dapagliflozin with extended-release metformin for type 2 diabetes.
- The financial trajectory of the combination is weaker than the broader Farxiga trajectory.
- Farxiga growth is driven increasingly by heart failure and chronic kidney disease, indications that do not require metformin.
- The original dapagliflozin compound patent has expired in the United States.
- Xigduo XR may retain formulation and method-of-use protections, but those claims are narrower and more vulnerable to design-around strategies.
- Generic dapagliflozin and generic dapagliflozin/metformin products create material price and volume risk.
- No biosimilar pathway applies because dapagliflozin/metformin is a small-molecule combination.
- Xigduo XR revenue is not separately disclosed, making franchise-level Farxiga sales an imperfect proxy.
- The product's strongest remaining commercial advantages are adherence, reduced pill burden, and integration into diabetes treatment.
- The leading long-term value resides in dapagliflozin's cardiorenal franchise, not in the metformin combination alone.
FAQs
Is dapagliflozin/metformin the same as Xigduo XR?
Yes. Xigduo XR is AstraZeneca's branded extended-release combination of dapagliflozin and metformin hydrochloride.
Can Xigduo XR be used for heart failure or chronic kidney disease?
The product is approved primarily for glycemic control in adults with type 2 diabetes. Farxiga has separate cardiorenal indications, but those indications do not automatically transfer to Xigduo XR.
Is dapagliflozin/metformin a biologic?
No. It is an oral small-molecule combination and is subject to generic-drug, not biosimilar, competition.
Why might a payer prefer separate dapagliflozin and metformin tablets?
Separate generic tablets can cost less and allow independent dose adjustment, discontinuation of metformin, or continuation of dapagliflozin when renal disease limits metformin use.
What determines the actual generic launch date?
The launch date depends on applicable Orange Book patents, patent-term adjustments, pediatric exclusivity, Paragraph IV litigation, settlement terms, regulatory approval, and the generic company's commercial decision.
References
-
U.S. Food and Drug Administration. (2014). Xigduo XR prescribing information. FDA.
-
AstraZeneca PLC. (2024). Annual report and Form 20-F 2023. AstraZeneca.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
AstraZeneca PLC. (2014). AstraZeneca assumes full global rights to dapagliflozin. AstraZeneca.
